As a standard treatment, Ribavirin is indicated for use in combination with Interferon Alpha to treat chronic Hepatitis C (HCV) infection. Ribavirin is a chemically derived pharmaceutical and belongs to a class of drugs called nucleoside analogues.
Status: Approved by EMA
Ribavirin is a chemically-derived synthetic analogue of guanosine that has a broad spectrum anti-viral effect by inhibiting RNA polymerase of various RNA viruses.
Biopartners has developed a patented, coated tablet formulation of ribavirin, which is a tablet for daily use, solely in combination with interferon alpha for the treatment of chronic, active hepatitis C.
Around 200 million people worldwide are infected with hepatitis C (about 3.3% of the world’s population) and over 80% are chronically infected, with 3-4 million new infections each year.